Abstract
Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.
Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs
Recent Patents on Anti-Cancer Drug Discovery
Title: RNA Interference as Therapeutics for Hepatocellular Carcinoma
Volume: 6 Issue: 1
Author(s): Chuanrui Xu, Susie A. Lee and Xin Chen
Affiliation:
Keywords: HCC, RNAi, Hepatocellular carcinoma, aflatoxin B1, Akt signaling, hepatocarcinogenesis, VEGFR, Drosha's cleavage, transcriptional gene silencing, RISC, TERT, IRES, DICER1, cadherin-17, STAT3, TGFBR, FoxM1B, CIAPIN1, metalloprotease, Transferrin, ALN-VSP02, SNALPs
Abstract: Hepatocellular carcinoma (HCC), a major form of primary liver cancer, is one of the leading causes of cancer related deaths worldwide. Hepatitis B and C infections are major risk factors for the development of HCC. Currently, the treatment options are rather limited, and the prognosis for this malignancy is poor for most of these patients. RNA interference has emerged as an innovative technology for gene silencing and as a potential therapeutic for various diseases, including cancer. HCC has been widely chosen as a model system for the development of RNAi therapy due to the convenience and availability of effective delivery of RNA molecules into liver tissues. Targets for HCC treatment include HBV and HCV viruses, oncogenes, as well as cellular genes mediating angiogenesis, tumor growth and metastasis. Here, we summarized the progress of RNAi therapeutics in HCC treatment, relevant patents, potential challenges and prospects in the future.
Export Options
About this article
Cite this article as:
Xu Chuanrui, A. Lee Susie and Chen Xin, RNA Interference as Therapeutics for Hepatocellular Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793980097
DOI https://dx.doi.org/10.2174/157489211793980097 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Meet Our Editorial Board Member
Pharmaceutical Nanotechnology Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Patent Selections
Recent Patents on Cardiovascular Drug Discovery Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis
Anti-Cancer Agents in Medicinal Chemistry Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Model Membrane and Cell Studies of Antimicrobial Activity of Melittin Analogues
Current Topics in Medicinal Chemistry MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Anti-Cancer Agents in Medicinal Chemistry Biomedical Imaging in Implantable Drug Delivery Systems
Current Drug Targets Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry